JP2019524865A - 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア - Google Patents

神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア Download PDF

Info

Publication number
JP2019524865A
JP2019524865A JP2019511620A JP2019511620A JP2019524865A JP 2019524865 A JP2019524865 A JP 2019524865A JP 2019511620 A JP2019511620 A JP 2019511620A JP 2019511620 A JP2019511620 A JP 2019511620A JP 2019524865 A JP2019524865 A JP 2019524865A
Authority
JP
Japan
Prior art keywords
day
microglia
compound
cromolyn
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019511620A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524865A5 (enExample
Inventor
デイビッド アール． エルマレー
デイビッド アール． エルマレー
ルドルフ イー． タンジ
ルドルフ イー． タンジ
ティモシー エム． シャウプ
ティモシー エム． シャウプ
アナ グリクラク
アナ グリクラク
Original Assignee
ザ ジェネラル ホスピタル コーポレイション
ザ ジェネラル ホスピタル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ジェネラル ホスピタル コーポレイション, ザ ジェネラル ホスピタル コーポレイション filed Critical ザ ジェネラル ホスピタル コーポレイション
Publication of JP2019524865A publication Critical patent/JP2019524865A/ja
Publication of JP2019524865A5 publication Critical patent/JP2019524865A5/ja
Priority to JP2022130220A priority Critical patent/JP2022171666A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019511620A 2016-08-31 2017-08-31 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア Pending JP2019524865A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022130220A JP2022171666A (ja) 2016-08-31 2022-08-17 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662382192P 2016-08-31 2016-08-31
US62/382,192 2016-08-31
PCT/US2017/049702 WO2018045217A1 (en) 2016-08-31 2017-08-31 Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022130220A Division JP2022171666A (ja) 2016-08-31 2022-08-17 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア

Publications (2)

Publication Number Publication Date
JP2019524865A true JP2019524865A (ja) 2019-09-05
JP2019524865A5 JP2019524865A5 (enExample) 2020-10-08

Family

ID=61309436

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019511620A Pending JP2019524865A (ja) 2016-08-31 2017-08-31 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア
JP2022130220A Pending JP2022171666A (ja) 2016-08-31 2022-08-17 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022130220A Pending JP2022171666A (ja) 2016-08-31 2022-08-17 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア

Country Status (8)

Country Link
US (3) US20190240194A1 (enExample)
EP (1) EP3506894B1 (enExample)
JP (2) JP2019524865A (enExample)
KR (1) KR20190044647A (enExample)
CN (2) CN116889562A (enExample)
AU (1) AU2017321782B2 (enExample)
CA (1) CA3033079A1 (enExample)
WO (1) WO2018045217A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN104869993B (zh) 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
AU2016359674A1 (en) * 2015-11-23 2018-06-14 The General Hospital Corporation Compositions and methods for treating ischemic stroke
US20190240194A1 (en) 2016-08-31 2019-08-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
BR112020000357A2 (pt) * 2017-07-08 2020-07-21 The General Hospital Corporation plataforma de triagem para identificar fármacos ou agentes terapêuticos para o tratamento da doença de alzheimer
CN111565711B (zh) 2017-07-20 2023-01-03 阿茨治疗股份有限公司 色甘酸钠和布洛芬的粉末化制剂
AU2019251191A1 (en) * 2018-04-09 2020-10-29 The General Hospital Corporation Combination therapies for the treatment of amyotropic lateral sclerosis and related disorders
KR20210071943A (ko) * 2018-07-02 2021-06-16 더 제너럴 하스피탈 코포레이션 크로몰린 소듐 및 α-락토스의 분말화된 제형
JP2021535181A (ja) * 2018-09-05 2021-12-16 ザ ジェネラル ホスピタル コーポレイション サイトカイン放出症候群を処置する方法
US12383528B2 (en) 2018-12-10 2025-08-12 The General Hospital Corporation Cromolyn esters and uses thereof
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
CN112375058A (zh) * 2020-11-11 2021-02-19 杭州卢普生物科技有限公司 色甘酸二乙酯和色甘酸钠的制备方法
US12612391B2 (en) 2020-12-28 2026-04-28 The General Hospital Corporation Cromolyn derivatives and uses thereof
WO2022178278A1 (en) * 2021-02-19 2022-08-25 The Trustees Of Columbia University In The City Of New York Compositions and methods for modeling human microglia

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013501046A (ja) * 2009-08-06 2013-01-10 ニューラルタス ファーマシューティカルズ， インコーポレイテッド マクロファージ関連障害の処置
WO2015002703A1 (en) * 2013-05-23 2015-01-08 Aztherapies, Inc Methods for delivering cromolyn
WO2015061397A1 (en) * 2013-10-22 2015-04-30 The General Hostpital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2015120392A1 (en) * 2014-02-10 2015-08-13 Patara Pharma, LLC Mast cell stabilizers for lung disease treatment
JP2015535249A (ja) * 2012-10-25 2015-12-10 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病と関連疾患の治療のための併用療法
JP2018534336A (ja) * 2015-11-19 2018-11-22 エーゼットセラピーズ， インコーポレイテッド アルツハイマー病および関連障害を処置するための方法
JP2018538273A (ja) * 2015-11-23 2018-12-27 エーゼットセラピーズ， インコーポレイテッド 虚血性脳卒中を処置するための組成物および方法

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1144905A (en) 1965-03-25 1969-03-12 Fisons Pharmaceuticals Ltd Substituted bis-(2-carboxy-chromonyl-oxy) derivatives and preparation and pharmaceutical compositions thereof
US3686412A (en) 1965-03-25 1972-08-22 Colin Fitzmaurice Compositions containing bis-chromonyl compounds for inhibiting antigen-antibody reactions
US3957965A (en) 1967-08-08 1976-05-18 Fisons Limited Sodium chromoglycate inhalation medicament
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1257162A (enExample) 1968-02-16 1971-12-15
US4405598A (en) 1976-01-30 1983-09-20 Fisons, Limited Composition for treating asthma
DE3104294A1 (de) 1981-02-07 1982-08-19 Hoechst Ag, 6000 Frankfurt Substituierte diazaspirodecane, ihre herstellung, ihre verwendung als stabilisatoren fuer organische polymere, sowie die so stabilisierten polymeren
US4429545A (en) 1981-08-03 1984-02-07 Ocean & Atmospheric Science, Inc. Solar heating system
BE897058A (fr) 1982-06-25 1983-12-16 Sandoz Sa Utilisation d'un derive du spiro-succinimide dans le traitement de la demence du type alzheimer
US4996296A (en) 1983-07-27 1991-02-26 Yeda Research & Development Co., Ltd. Cromolyn binding protein in highly purifed form, and methods for the isolation thereof
US4919915A (en) 1987-03-03 1990-04-24 Paul Averback Method for detecting the ability to prevent red-to-green congophilic birefringence
US5231170A (en) 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
JPH05501505A (ja) 1989-04-28 1993-03-25 ライカー　ラボラトリーズ，インコーポレイティド 乾燥粉末吸入装置
US5376386A (en) 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
DE4405387A1 (de) 1994-02-19 1995-08-24 Hoechst Ag Verfahren zur Herstellung von Polyalkyl-1-oxa-diazaspirodecan-Verbindungen
US6168776B1 (en) 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
CA2174583A1 (en) 1995-05-05 1996-11-06 Alexander Chucholowski Sulfuric acid esters of sugar alcohols
US6026809A (en) 1996-01-25 2000-02-22 Microdose Technologies, Inc. Inhalation device
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
ATE248583T1 (de) 1997-09-29 2003-09-15 Nektar Therapeutics In dosierinhalatoren verwendbare, stabilisierte zubereitungen
US5904937A (en) 1997-10-03 1999-05-18 Fmc Corporation Taste masked pharmaceutical compositions
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
KR100561223B1 (ko) 1998-06-12 2006-03-15 마이크로도스 테크놀로지즈 인코포레이티드 약제 및 약물의 계량, 포장 및 운송
US6197963B1 (en) 1998-08-13 2001-03-06 The Trustees Of The University Of Pennsylvania Non-peptide peptidomimetics
CN1150895C (zh) 1998-11-13 2004-05-26 杰格研究股份公司 用于吸入给药的干粉
EP1140105B1 (en) 1998-12-24 2003-10-22 Janssen Pharmaceutica N.V. Controlled release galantamine composition
JP2001151673A (ja) 1999-09-06 2001-06-05 Nikken Chem Co Ltd 吸入用粉末製剤の製造方法
US20020107173A1 (en) 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
US20020009491A1 (en) 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
WO2001062284A2 (en) 2000-02-21 2001-08-30 Pharmexa A/S Novel method for down-regulation of amyloid
AU5702201A (en) 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
US20080021085A1 (en) 2000-04-13 2008-01-24 Mayo Foundation For Medical Education And Research Method of reducing abeta42 and treating diseases
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
AR035642A1 (es) 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor
US20020016359A1 (en) 2000-06-29 2002-02-07 Hellberg Mark R. Compositions and methods of treating neurodegenerative diseases
US8519005B2 (en) 2000-07-27 2013-08-27 Thomas N. Thomas Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy
FR2815030A1 (fr) 2000-10-05 2002-04-12 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant et leur utilisation pour la preparation de medicaments
US6511960B2 (en) 2001-01-05 2003-01-28 Alphamed Pharmaceuticals Corp Cromolyn for eye and ear infections
CA2444214A1 (en) 2001-04-23 2002-10-31 The Trustees Of The University Of Pennsylvania Amyloid plaque aggregation inhibitors and diagnostic imaging agents
CA2466863A1 (en) 2001-11-29 2003-06-05 Emisphere Technologies, Inc. Oral pharmaceutical compositions comprising cromolyn sodium and an acylated amino acid
CN1668354A (zh) 2002-05-10 2005-09-14 奥里尔治疗公司 干粉吸入器、相关泡状体装置以及分配干粉物质和制造泡状体包装的相关方法
EP1601379A1 (en) * 2003-02-13 2005-12-07 Licentia OY Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of a patient subjected to thrombolyses
WO2004071531A1 (en) 2003-02-13 2004-08-26 Licentia Oy Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
US20040223918A1 (en) 2003-05-07 2004-11-11 Chrysalis Technologies Incorporated Aerosolization of cromolyn sodium using a capillary aerosol generator
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
WO2005044187A2 (en) 2003-10-28 2005-05-19 Glaxo Group Limited Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
DE10355559A1 (de) 2003-11-21 2005-06-23 Orthogen Ag Transskin
WO2005063732A1 (en) 2003-12-23 2005-07-14 Microbia, Inc. Compounds and methods for the treatment of asthma
US20070093457A1 (en) 2004-02-11 2007-04-26 Nadir Arber Compositions for treatment of cancer and inflammation with curcumin and at least one nsaid
US20050182044A1 (en) 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
WO2006001877A2 (en) 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
BRPI0510119A (pt) 2004-04-23 2007-09-25 Cydex Inc formulação para dpi contendo sulfoaquil éter de ciclodextrina
ES2339790T3 (es) 2004-08-30 2010-05-25 Seo Hong Yoo Efecto neuroprotector de udca solubilizado en modelo isquemico focal.
EP1814558B1 (en) * 2004-11-01 2010-12-15 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
CA2607475A1 (en) 2005-04-22 2006-11-02 Genentech, Inc. Method for treating dementia or alzheimer's disease with a cd20 antibody
JP2008545663A (ja) 2005-05-27 2008-12-18 クイーンズ ユニバーシティ アット キングストン タンパク質フォールディング障害の治療
US20070178166A1 (en) 2005-12-15 2007-08-02 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
US8263645B2 (en) 2006-02-03 2012-09-11 Pari Pharma Gmbh Disodium cromoglycate compositions and methods for administering same
AR059356A1 (es) 2006-02-14 2008-03-26 Astrazeneca Ab Nuevos radioligandos
US7700618B2 (en) 2006-03-06 2010-04-20 Pfizer Inc Sulfonyl benzimidazole derivatives
WO2007101353A1 (en) 2006-03-09 2007-09-13 Waratah Pharmaceuticals Inc. A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation
EP2023919A4 (en) 2006-05-08 2010-12-22 Molecular Neuroimaging Llc COMPOUNDS AND AMYLOID PROBES FOR THERAPY AND IMAGING USES
US8445437B2 (en) 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
US20100173960A1 (en) 2006-09-21 2010-07-08 Antonio Cruz The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases
US20100292157A1 (en) 2006-11-24 2010-11-18 Antonio Cruz Combination Treatments for Alzheimer's Disease and Similar Diseases
ES2468551T3 (es) 2007-04-18 2014-06-16 Probiodrug Ag Derivados de nitrovinil-diamina como inhibidores de la glutaminil ciclasa
WO2008131298A2 (en) 2007-04-18 2008-10-30 Elan Pharma International Limited Prevention and treatment of cerebral amyloid angiopathy
WO2008134618A2 (en) 2007-04-27 2008-11-06 The General Hospital Corporation Novel imaging tracers for early detection and treatment of amyloid plaques caused by alzheimer's disease and related disorders
CA2693771A1 (en) 2007-07-13 2009-01-22 Abbott Biotechnology Ltd. Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor
GB0714134D0 (en) 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP3231804B1 (en) 2008-03-21 2021-03-03 The General Hospital Corporation Compounds and compositions for the detection and treatment of alzheimer's disease and related disorders
WO2009133128A1 (en) 2008-04-29 2009-11-05 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
WO2010084767A1 (en) 2009-01-22 2010-07-29 Raqualia Pharma Inc. N-substituted saturated heterocyclic sulfone compounds with cb2 receptor agonistic activity
US8381454B1 (en) 2009-01-23 2013-02-26 Markus R. Robinson Segmented, elongated, expandable, 4-season, double-walled, low-cost, rigid extruded plastic panel structures
EP3567033A1 (en) * 2009-01-29 2019-11-13 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
AR076105A1 (es) 2009-03-11 2011-05-18 Plexxikon Inc Derivados pirrol[2,3-b]piridina para inhibir la raf quinasa
WO2010107702A1 (en) 2009-03-16 2010-09-23 Ipintl, Llc Treating alzheimer's disease and osteoporosis and reducing aging
ES2457442T3 (es) 2009-05-08 2014-04-25 Pari Pharma Gmbh Formulaciones farmacéuticas concentradas estabilizadoras de los mastocitos
KR20170061177A (ko) 2009-09-24 2017-06-02 위스타 레보레이토리스 리미티드 결정질 메틸티오니늄 클로라이드（메틸렌 블루） 수화물
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US20110262442A1 (en) 2009-11-06 2011-10-27 Adenios, Inc. Compositions for treating cns disorders
MX337603B (es) 2009-11-30 2016-03-10 Adare Pharmaceuticals Inc Composiciones y tabletas farmaceuticas con recubrimiento compresible y metodos de fabricacion.
US20110256064A1 (en) 2010-04-16 2011-10-20 Ac Immune, S.A. Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins
WO2011136754A1 (en) 2010-04-26 2011-11-03 Mahmut Bilgic A medicament developed for the treatment of respiratory diseases
AU2011289172B2 (en) * 2010-08-12 2015-09-24 Revalesio Corporation Compositions and methods for treatment of taupathy
WO2012041717A1 (en) 2010-09-30 2012-04-05 Chiesi Farmaceutici S.P.A. Use of magnesium stearate in dry powder formulations for inhalation
US20120121656A1 (en) 2010-11-15 2012-05-17 Revalesio Corporation Methods and compositions for protecting against neurotoxicity of a neurotoxic agent, and improving motor coordination associated with a neurodegenerative condition or disease
KR101888713B1 (ko) 2011-02-11 2018-08-14 위스타 레보레이토리스 리미티드 페노티아진 디아미늄 염 및 이의 용도
SG11201406142XA (en) 2012-03-27 2014-10-30 Univ Duke Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage
EP2854781A4 (en) 2012-05-25 2016-04-13 Xlear Inc XYLITOL-BASED ANTIMUKOSAL COMPOSITIONS AND ASSOCIATED METHODS AND COMPOSITIONS
CA2883130A1 (en) * 2012-08-31 2014-03-06 The General Hospital Corporation Biotin complexes for treatment and diagnosis of alzheimer's disease
WO2014065275A1 (ja) 2012-10-23 2014-05-01 国立大学法人福井大学 腫瘍融解症候群の治療薬及び予防薬
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
CN104288168B (zh) * 2013-07-17 2017-08-18 吉林敖东洮南药业股份有限公司 延龄草苷在制备用于治疗和/或预防小胶质细胞介导的疾病的药物中的用途
PL3104853T3 (pl) 2014-02-10 2020-05-18 Respivant Sciences Gmbh Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych
CA2967659A1 (en) 2014-11-21 2016-05-26 Biohaven Pharmaceutical Holding Company Ltd. Sublingual administration of riluzole
WO2016196401A1 (en) 2015-05-29 2016-12-08 The Texas A&M University System Antimicrobial and anti-inflammatory compositions
WO2017027387A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
EP3368032A1 (en) * 2015-10-28 2018-09-05 AB Science Use of masitinib and other mast cell inhibitors for treatment of parkinson's disease
EA038531B1 (ru) * 2016-03-25 2021-09-10 Аб Сьянс Способ лечения амиотрофного латерального склероза, применение фармацевтической композиции, содержащей мазитиниб
US20190240194A1 (en) 2016-08-31 2019-08-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
MY204310A (en) 2016-09-08 2024-08-22 Emergo Therapeutics Inc Mast cell stabilizers for treatment of hypercytokinemia and viral infection
CN111565711B (zh) 2017-07-20 2023-01-03 阿茨治疗股份有限公司 色甘酸钠和布洛芬的粉末化制剂
CN108164409B (zh) 2018-01-24 2021-06-18 温州医科大学 一种2-亚苄基-1-茚酮类似物及应用
AU2019251191A1 (en) 2018-04-09 2020-10-29 The General Hospital Corporation Combination therapies for the treatment of amyotropic lateral sclerosis and related disorders
CN108403708B (zh) 2018-05-22 2019-06-14 滨州医学院 秦皮苷在制备预防或治疗急性呼吸窘迫综合征药物中的应用
KR20210071943A (ko) 2018-07-02 2021-06-16 더 제너럴 하스피탈 코포레이션 크로몰린 소듐 및 α-락토스의 분말화된 제형
JP2021535181A (ja) 2018-09-05 2021-12-16 ザ ジェネラル ホスピタル コーポレイション サイトカイン放出症候群を処置する方法
US12383528B2 (en) 2018-12-10 2025-08-12 The General Hospital Corporation Cromolyn esters and uses thereof
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
WO2021248022A1 (en) 2020-06-04 2021-12-09 The General Hospital Corporation Methods of treating a coronavirus infection
US12612391B2 (en) 2020-12-28 2026-04-28 The General Hospital Corporation Cromolyn derivatives and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013501046A (ja) * 2009-08-06 2013-01-10 ニューラルタス ファーマシューティカルズ， インコーポレイテッド マクロファージ関連障害の処置
JP2015535249A (ja) * 2012-10-25 2015-12-10 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病と関連疾患の治療のための併用療法
WO2015002703A1 (en) * 2013-05-23 2015-01-08 Aztherapies, Inc Methods for delivering cromolyn
WO2015061397A1 (en) * 2013-10-22 2015-04-30 The General Hostpital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2015120392A1 (en) * 2014-02-10 2015-08-13 Patara Pharma, LLC Mast cell stabilizers for lung disease treatment
JP2018534336A (ja) * 2015-11-19 2018-11-22 エーゼットセラピーズ， インコーポレイテッド アルツハイマー病および関連障害を処置するための方法
JP2018538273A (ja) * 2015-11-23 2018-12-27 エーゼットセラピーズ， インコーポレイテッド 虚血性脳卒中を処置するための組成物および方法

Also Published As

Publication number Publication date
EP3506894B1 (en) 2023-08-23
CA3033079A1 (en) 2018-03-08
US20240082207A1 (en) 2024-03-14
WO2018045217A1 (en) 2018-03-08
US11679095B2 (en) 2023-06-20
EP3506894C0 (en) 2023-08-23
US20220079914A1 (en) 2022-03-17
JP2022171666A (ja) 2022-11-11
US20190240194A1 (en) 2019-08-08
AU2017321782B2 (en) 2022-03-10
WO2018045217A8 (en) 2019-03-14
EP3506894A1 (en) 2019-07-10
CN109922800A (zh) 2019-06-21
AU2017321782A1 (en) 2019-03-07
CN109922800B (zh) 2023-06-13
KR20190044647A (ko) 2019-04-30
CN116889562A (zh) 2023-10-17
EP3506894A4 (en) 2020-07-29

Similar Documents

Publication Publication Date Title
US11679095B2 (en) Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
US20220226270A1 (en) Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
JP2025164962A (ja) ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体
US20100004244A1 (en) Use of cb2 receptor agonists for promoting neurogenesis
JP2021535181A (ja) サイトカイン放出症候群を処置する方法
CN103298777A (zh) 苯基酮羧酸盐化合物和其药学用途
JP4788999B2 (ja) 分枝鎖カルボン酸化合物およびその用途
US10287227B2 (en) Myricanol derivatives and uses thereof for treatment of neurodegenerative diseases
CN117136050A (zh) 用于使用大麻素治疗神经元病症的组合物和方法
KR102946349B1 (ko) 신경퇴행성 질환의 치료약물 및 그의 응용
CN1662242B (zh) 用于治疗与神经营养蛋白相关的疾病的药物组合物
KR102920650B1 (ko) 류코트리엔 합성 억제제
JP2021520413A (ja) 眼科的状態のための療法
JP7382944B2 (ja) 神経変性疾患を予防・治療するための新規な化合物及びその応用
KR102374047B1 (ko) N,N′-디아세틸-p-페닐렌디아민 화합물을 유효성분으로 포함하는 알츠하이머병 예방, 개선 또는 치료용 조성물
JP2022529742A (ja) 神経修復方法
JP2021520412A (ja) タンパク質ミスフォールディング疾患のための療法
JP7702145B2 (ja) ミトコンドリア機能障害改善剤
KR20240169190A (ko) 자가면역 질환 치료를 위한 신규 MyD88 억제제 및 이의 용도
KR20250010571A (ko) 신규한 고리 구조의 트리아졸 화합물, 이의 제조방법 및 이의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210720

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211217

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220817

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220817

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220906

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221011

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221018

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221104

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221115